Is there a correlation with severity of rash as an adverse event and response rate with capivasertib?

While it is tempting to hope that patients with significant side effects on targeted therapies might be more likely to demonstrate an antitumor response to that treatment, and there is limited data to suggest a possible correlation between immune-related adverse events and response to immunotherapy, I am not aware of any correlation between the development or severity of rash on capivasertib (if such data is available I would be very interested to be informed of it) and the likelihood or duration of response to that treatment, and certainly no indication that patients should 'grin and bear' a symptomatic rash that is not responding to other interventions as opposed to reducing the dose or delaying the resumption of treatment to allow the ra...

I am not aware about correlation between severity of rash and response to capivasertib.